I gG4-related disease (IgG4-RD) is a multi-organ fibroinflammatory syndrome that potentially can involve any organ system. 1 IgG4-related pancreatitis, also known as type 1 autoimmune pancreatitis (AIP), and IgG4-related sclerosing cholangitis are terms used to describe pancreatic and biliary involvement in IgG4-RD, respectively. Although pancreaticobiliary IgG4-RD (PB IgG4-RD) typically is steroid-responsive, relapses are common after steroid withdrawal with nearly 60% of relapses occurring within the first year and more than 90% within 3 years after steroid treatment. 2 Long-term, low-dose corticosteroid maintenance effectively reduces the relapse rate but does not alter the likelihood of relapse after eventual steroid withdrawal. 3, 4 The risks of indefinite corticosteroid therapy are not insignificant.
Rituximab, a chimeric monoclonal antibody targeting the CD 20 antigen on B lymphocytes has been shown to be an effective treatment for IgG4-RD. 5 However, in 1 prospective series, only 40% of patients remained in remission at 1 year after induction treatment with 2 doses of rituximab, and in a more recent series with a median postrituximab follow-up period of 252 days relapse was noted in 37% of patients who initially responded to 2 doses of rituximab. 5, 6 The efficacy of rituximab maintenance therapy compared with induction therapy alone and the optimum dose and duration of maintenance treatment is unknown. In this study, we aimed to compare rates of response, relapse, and adverse events in patients who received induction rituximab therapy alone with those who received induction followed by rituximab maintenance.
Materials and Methods

Study Design
The study was approved by the Mayo Clinic Rochester (MCR) Institutional Review Board. The MCR institutional database was searched using the Advanced Cohort Explorer search tool to identify patients with PB IgG4-RD who had been treated with rituximab between January 2005 and December 2015. Subjects identified by this search method were invited to participate by mail. MCR medical records were reviewed to obtain demographic information, organ systems involved by IgG4-RD at presentation, laboratory values, radiologic findings, and treatment history before administration of rituximab. Standardized telephone interviews were conducted to obtain follow-up data from those subjects who received maintenance rituximab infusions at other institutions, and with subjects for whom no recent (<12 mo) followup data were available in the MCR records. Data collected from subjects include recurrence of IgG4-RD symptoms since their last MCR visit, evaluation and treatment given, current symptoms of IgG4-RD, and current medical treatment for IgG4-RD (if any). All medical records since the date of the subject's last visit to MCR were obtained for those who had undergone diagnostic tests or received therapy for IgG4-RD since their last MCR visit. Rituximab infusion records also were obtained for subjects who received infusions elsewhere. Study subjects were divided into 2 groups: group 1 had rituximab induction only (375 mg/m 2 weekly Â 4 or 1000 mg biweekly Â 2), and group 2 had rituximab induction followed by maintenance (375 mg/m 2 or 1000 mg every 2-6 mo). Of the 43 patients included, short-term outcomes in 23 have been reported in 1 or more previous publications. 5, 7 However, long-term follow-up evaluation and relapse, the principal focus of this article, for these patients were not reported. The IgG4-Responder Index (IgG4-RI) scores were calculated retrospectively without including the serum IgG4 concentration, as previously described. 8 To calculate the IgG4-RI score, disease activity in each organ system affected by IgG4-RD is scored as 4 if disease activity has worsened despite treatment, scored as 3 if new or recurrent disease activity is present, scored as 2 if there is persistent disease activity unchanged from the previous visit, scored as 1 if disease activity is improved but still present, and scored as 0 if the previous disease activity has resolved. The organ system score is doubled if there is an urgent need to initiate treatment owing to disease activity in that particular organ system. Damage from previously active disease is noted but does not receive a score. The score from each organ system is summed to obtain the IgG4-RD RI score. An IgG4-RD RI scoring sheet has been published and can be used for scoring, except that the serum IgG4 concentration should not be included. 8 In the current study the postinduction IgG4-RI score was calculated from data available 2 to 4 months after induction therapy.
Definitions
Pancreaticobiliary IgG4-RD was diagnosed on the basis of history, physical examination, laboratory and imaging studies, and biopsy. For those with pancreatic involvement the diagnosis was made in accordance with the International Consensus Diagnostic Criteria for definite type 1 AIP. 9 For patients with biliary involvement the diagnosis was based on histologic confirmation of IgG4-RD in other affected organ sites or a combination of imaging findings and response to corticosteroids after cytology and/or biopsy specimens did not show a biliary tract malignancy. Complete remission was defined as resolution of symptoms and imaging or laboratory findings of active IgG4-RD (clinical, radiographic, or biochemical), without an ongoing need for steroid therapy. Partial remission was defined as improvement without resolution of inflammatory changes, without an ongoing need for steroid therapy. Improvement without resolution of inflammatory changes along with an ongoing need for steroids to maintain response was termed incomplete remission. Relapse was defined as the development of radiologic findings or biochemical abnormalities consistent with a new or worsening inflammatory process requiring re-treatment or an increase in the dose of steroids that previously was being tapered.
Study Outcomes
The primary outcome of the study was relapse rates over time in patients who did or did not receive rituximab maintenance therapy after initial rituximab induction therapy. Secondary outcomes included assessing disease response to initial rituximab induction therapy, duration to relapse after last dose of rituximab in study groups, adverse event rates, and identifying potential predictors of relapse.
Statistical Analysis
Continuous variables are summarized as means (SD) or median (25th, 75th percentiles) as indicated. Discrete variables are presented as frequency (percentage).
Group differences were tested with the rank-sum test for continuous variables and the chi-squared test for categoric variables. Kaplan-Meier methods were used to estimate the risk of relapse, with comparisons between the 2 groups tested by the log-rank test. The end of induction treatment was used as time zero for the purposes of follow-up evaluation. Cox regression models were fit separately for each potential relapse predictor to estimate unadjusted associations with relapse. Cox regression models were used to assess potential relapse predictors. Laboratory values (eg, eosinophils) were analyzed both continuously (using the natural logarithm of values to reduce the influence of outliers) and dichotomizing according to upper limits of normal.
Results
Patient Characteristics
Forty-three patients met the study inclusion criteria (14 in group 1, 29 in group 2). Four subjects could not be contacted for a telephone interview and had less than 1 year of follow-up data available; for the remainder, more than 1 year of follow-up evaluation was obtained. For rituximab induction, 19 patients received 375 mg/m 2 weekly Â 4 and 24 patients were treated with 1000 mg biweekly Â 2. Seven patients (16%) received rituximab as first-line therapy, generally because of a history of steroid intolerance or poorly controlled diabetes mellitus, and the remainder had relapsed after prior treatment with steroids with or without immunomodulators. Age, sex, prior corticosteroid and immunomodulator use, biliary stricture, and disease duration were not significantly different for the 2 groups (Table 1) .
Treatment Outcomes
Thirty-seven (86%) patients were in complete or partial remission and had discontinued steroids successfully at 6 months after rituximab initiation. The majority of these patients (30 of 43; 70%) were steroid- (11, 33) . The median duration of postinduction follow-up evaluation was 34 months (27, 42) in group 1 and 27 months (15, 54) in group 2 (P ¼ .99). Relapse was observed in 9 patients, including 5 patients in group 1 and 4 patients in group 2 (1 while on maintenance therapy, 3 others after stopping maintenance therapy). The relapse rate in group 1 was significantly higher than that in group 2 (3-year event rate, 45% vs 11%; P ¼ .034) (Figure 1 ). Among patients who relapsed, the median duration from the last dose of rituximab to relapse was 15 months (7, 28) in group 1 and 14 months (3, 27) in group 2 (P ¼ .81). Among patients receiving maintenance therapy, relapse was not associated with the overall duration of maintenance treatment or the interval between maintenance doses. Figure 2 shows the relapse rates over time after the last rituximab infusion for both groups. There is a trend toward a lower post-treatment relapse rate in patients who received maintenance therapy, but the difference in relapse rates between these small patient groups was not significant (P ¼ .12)
Rituximab Adverse Effects
Infusion reactions and infections were the main observed adverse effects of rituximab in this study cohort. Eight patients (4 in group 1 [29%] and 4 [14%] in group 2; P ¼ .22) developed mild infusion reactions to rituximab, one of which was during the index infusion, and all of which were treated successfully without hospitalization or discontinuation of therapy. Eight episodes of infection requiring antibiotic therapy or hospitalization were noted in 6 patients during rituximab treatment (6 of 43; 14%). This included pneumonia (3 episodes), urinary tract sepsis (1 episode), Clostridium difficile colitis (1 episode), dental abscess (1 episode), and sinusitis (1 episode). One patient developed both urosepsis and pneumonia in consecutive years while on maintenance therapy. Of the 3 patients who developed pneumonia, 2 were on maintenance therapy and 1 had completed induction at the time of the pneumonia diagnosis. In 1 of the patients pneumonia was complicated by fatal gram-positive sepsis and respiratory failure. C difficile colitis occurred in the setting of antibiotic use in the patient who developed a dental abscess. One patient developed diverticulitis requiring hospitalization and improved with conservative treatment, and 1 patient developed severe neutropenia that was treated with granulocyte colony-stimulating factor. All infectious complications were observed in group 2 and all but 1 were noted during the maintenance therapy phase (P ¼ .067). There was no statistical correlation between serum total IgG levels and occurrence of infection. One patient was diagnosed with malignant melanoma at 3 months after rituximab induction, and we deemed this unrelated to rituximab treatment. Table 2 shows factors associated with relapse in univariate analysis of the entire study cohort. Factors that were associated significantly with a higher likelihood of relapse included younger age (mean, 54 y in patients with relapse vs 64 y in patients without relapse) and a higher IgG4-RI score after induction rituximab therapy (median score, 1 [range, 0-2] in patients with relapse vs 0 [range, 0-2] in patients without relapse). Four of 25 patients with a postinduction IgG4-RI score of 0 experienced subsequent relapse vs 5 of 17 with a score greater than 0 (16% vs 29%; P ¼ .30). Lower blood eosinophil counts after induction therapy were associated with a significantly higher likelihood of relapse (P ¼ .027 analyzed continuously), although Figure 3 , alkaline phosphatase increases above the upper limit of normal were associated with a higher likelihood of relapse whether or not this laboratory value normalized after induction rituximab therapy. Among patients with a prerituximab serum alkaline phosphatase concentration above the upper limit of normal, the hazard ratio for relapse was 3.26 (95% CI, 0.46-23.3) if the alkaline phosphatase level normalized after induction rituximab therapy and 6.31 (95% CI, 1.2-3) if the alkaline phosphatase level did not normalize after induction therapy.
Factors Associated With Relapse
Discussion
Management of relapsing pancreaticobiliary IgG4-RD may be challenging and therapeutic options are limited. In this study, we describe a large clinical experience of rituximab use for treatment of PB IgG4-RD. Most of our patients received rituximab because they were in relapse after prior steroid therapy, and the majority had biliary involvement, which has been shown in previous studies to be a predictor of relapse. 10 Induction rituximab therapy successfully induced remission in the great majority of patients. Relapse was uncommon during rituximab maintenance therapy, and rituximab maintenance therapy was associated with a significantly longer relapsefree period when compared with rituximab induction therapy alone. Relapses occurred after conclusion of maintenance therapy at a lower but not statistically different rate than after induction therapy alone, and the mean time to relapse after the last rituximab infusion was similar in both groups. Because of the small sample size in this portion of the analysis it is unclear whether rituximab maintenance therapy alters the natural history of the disease after therapy stops. Steroids typically induce remission in PB-IgG4-RD both for the index episode as well as subsequent relapses, but relapses are common after steroid discontinuation. 11 In the prerituximab era, medical treatment options for relapsing PB-IgG4-RD were limited to steroid maintenance therapy with or without steroid-sparing immunomodulators. In a randomized controlled trial conducted in patients with AIP, Masamune et al 4 showed that maintaining patients on 5 to 7.5 mg prednisolone for 3 years was effective at reducing relapse rates when compared with steroid taper and cessation. Despite the relative efficacy of this strategy, 1 in 4 patients relapsed while on steroid maintenance. This recrudescence of disease often requires rescue therapy with high-dose steroids and eventually results in cumulative exposure to large doses of corticosteroids with resultant deleterious effects on bone health and glycemic status in the setting of concomitant endocrine and exocrine pancreatic dysfunction. In our experience, when compared with steroids alone, the addition of traditional oral immunomodulators did not change relapse rates over time. 7 The patients presented in this study represent a minority of all PB-IgG4-RD patients seen in our clinic. We consider corticosteroids to be the first-line treatment for this disease, and offer rituximab therapy to patients who are in relapse after prior steroid treatment, have recrudescent disease preventing complete steroid discontinuation, or have contraindications to steroid therapy. We do not routinely use oral immunomodulators such as azathioprine in the treatment of PB-IgG4-RD because in our experience these agents are not efficacious for prevention of relapse and frequently cause side effects. 7 Only 7 of the 43 patients in this study had received no prior medical therapy, and more than half had been treated previously with both steroids and oral immunomodulators. In our initial experience we tended to prescribe rituximab maintenance therapy for most patients receiving rituximab, and first began recommending induction therapy alone to most patients in the context of a clinical trial. 5 We did not select patients for maintenance therapy based on particular clinical features, and the 2 patient groups in this study were matched evenly on baseline characteristics.
The efficacy of rituximab in treating IgG4-related cholangitis was described in 2008, and supported by a subsequent series of 12 patients with PB-IgG4-RD. 7, 12 These patients all were treated with induction followed by maintenance therapy. Eleven patients (11 of 12; 92%) responded to rituximab therapy and during a median follow-up period of 10.6 months there were no relapses. Subsequently, the use of rituximab for various manifestations of IgG4-RD was described in a prospective clinical trial that included 30 patients treated with induction alone. 5 All patients in that study were treated with 2 infusions of rituximab administered 2 weeks apart. A complete or partial response was seen in 97% of patients and 77% were steroid free without relapse at 6 months. In a retrospective study of rituximab induction therapy for various manifestations of IgG4-RD almost half of patients had experienced relapse by 12 months. 6 The current study compared rituximab induction and maintenance therapy with induction alone in IgG4-RD. Rituximab induction therapy was highly effective in this population of patients with relapsing or recrudescent disease, and the relapse rate over time was significantly lower in patients treated with maintenance dosing. Overall, rituximab was better tolerated than immunomodulators; however, we observed clinically significant infections in 6 patients. All but 1 infection occurred during maintenance therapy.
Factors such as male sex, young age, multiorgan, and proximal biliary involvement are associated with a higher risk of relapse among IgG4-RD patients treated with steroid therapy. 11, 13 We similarly found that relapse after rituximab therapy is associated with younger age and biliary disease (as manifested by serum alkaline phosphatase increases). A prior retrospective cohort study of rituximab treatment in patients with various manifestations of IgG4-RD identified baseline serum IgG4, IgE, and blood eosinophil concentrations as predictors of relapse. 6 We were unable to confirm these findings, although we did not have enough baseline IgE levels available to analyze this variable, and our study's small sample size limited the statistical power of our analysis. Different clinical manifestations of IgG4-RD may have different relapse rates, and it is possible that predictors of relapse will vary based on the pattern of organ involvement.
We identified 2 postinduction clinical measures that were associated with relapse, the serum alkaline phosphatase concentration and the IgG4-RI score. The IgG4-RI is an assessment tool that quantifies disease activity across all organ systems, taking into account symptoms, laboratory and imaging findings, and urgency of treatment. 8 Disease activity in each organ system is scored as 0 (normal or resolved), 1 (improved), 2 (persistent), 3 (new/recurrent), or 4 (worsened despite treatment). Scores are doubled if urgent treatment of that organ system is indicated, and summed for all involved organ systems. The presence of organ damage also was recorded, although it was not included in the score. Although there is some subjectivity in IgG4-RI scoring, the association of postinduction scores with subsequent relapse is plausible and potentially useful when considering whether to administer maintenance rituximab therapy. Similarly, relapse is more common among IgG4-RD patients who have prerituximab increases of the serum alkaline phosphatase level, and relapse is even more likely if their serum alkaline phosphatase concentration does not normalize after induction therapy. These factors, together with patient age, might be useful when deciding whether to prescribe maintenance rituximab therapy in some cases.
Our study had several limitations. Although this was a large series of rituximab use in PB-IgG4-RD, the small sample size limited a robust assessment of the study outcomes. The patients were heterogeneous with regard to prior treatment history, potentially confounding some analyses, but also increasing study generalizability. Because this was a retrospective study we cannot exclude the possibility of undetected clinical biases in the use of rituximab maintenance therapy. In addition, the interval between doses for patients in the maintenance group was variable and hence no specific recommendations can be made based on these results regarding the optimum interval between doses. Despite the variability in the dosing regimen one of the major strengths of the study was the length of follow-up evaluation after discontinuation of rituximab, providing useful information on the time to relapse after treatment. This study provides preliminary data useful for the design of subsequent clinical trials that are necessary to better understand the indications for maintenance therapy as well as the optimum dosing regimen and duration of maintenance therapy.
In conclusion, this study shows the effectiveness of maintenance rituximab therapy in preventing relapse of pancreaticobiliary IgG4-RD. Relapses are unlikely during maintenance therapy but may occur after discontinuation of maintenance therapy, and infectious complications appear to be more common in patients receiving maintenance rituximab treatment. Younger age, postinduction IgG4-RD RI score, and increase of the serum alkaline phosphatase concentration are associated with relapse and may be factors to consider when choosing whether or not to advise maintenance rituximab. Further prospective studies are needed to better identify the indications, dosing interval, and duration of rituximab maintenance therapy.
